This company has been acquired
APGN Stock Overview
Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Apexigen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.39 |
| 52 Week High | US$8.28 |
| 52 Week Low | US$0.33 |
| Beta | 3.62 |
| 11 Month Change | -6.07% |
| 3 Month Change | -28.69% |
| 1 Year Change | -92.22% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.38% |
Recent News & Updates
Shareholder Returns
| APGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.8% | 4.3% | 1.6% |
| 1Y | -92.2% | 18.8% | 32.3% |
Return vs Industry: APGN underperformed the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: APGN underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| APGN volatility | |
|---|---|
| APGN Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: APGN's share price has been volatile over the past 3 months.
Volatility Over Time: APGN's weekly volatility has decreased from 25% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 11 | Xiaodong Yang | www.apexigen.com |
Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.
Apexigen, Inc. Fundamentals Summary
| APGN fundamental statistics | |
|---|---|
| Market cap | US$9.57m |
| Earnings (TTM) | -US$27.02m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs APGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APGN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$27.02m |
| Earnings | -US$27.02m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did APGN perform over the long term?
See historical performance and comparison